TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers at the University Hospital of Bonn and the University of Bonn report directly reprogramming human red blood cell precursors into neural stem cells in a laboratory. The cells’ epigenetic clocks reset gradually; cells from an 80-year-old donor were measured as having a molecular age of less than 20 years. The finding is a cell-reprogramming result, not evidence of a rejuvenation treatment for people.
Researchers at the University Hospital of Bonn and the University of Bonn report that they converted human red blood cell precursors directly into neural stem cells in laboratory experiments, while the cells’ measured epigenetic age fell substantially. In one example reported by the team, cells from an 80-year-old donor had a molecular age of less than 20 years after reprogramming. The work, published in Aging Cell, is a test-tube finding, not a demonstrated way to reverse aging in a person.
The researchers used a combination of transcription factors to change the developmental identity of the blood-cell precursors. Such factors influence which genetic instructions a cell reads, allowing it to take on a different cell fate. The Bonn team says the cells were converted directly into neural stem cells, without first becoming pluripotent stem cells, a more flexible intermediate state that can give rise to many cell types.
To assess age-related changes, the team examined epigenetic clocks, which estimate cellular age using DNA modifications associated with aging. These modifications do not alter the DNA sequence itself; they relate to how genetic information is regulated. The researchers report that these clock readings shifted toward a younger age during conversion. The reported age of less than 20 years refers to a molecular measure in the cells, not the donor’s age or a measured change in the donor’s body.
The process was gradual: the researchers tracked reprogramming for more than 100 days. They say this extended period could let scientists study how cellular age markers change over time and test which factors speed up or slow down that process. The study is titled “Protracted Fate Acquisition and Epigenetic De-Aging During Induced Neural Stem Cell Conversion of Human Blood Cells” and was published in 2026 in Aging Cell.
A Slow Model for Studying Cell Age
The work’s immediate value is as a research model, rather than a prospective therapy. Because the reported age-marker changes unfold over weeks, researchers may be able to follow how cell identity and epigenetic age change together, and investigate the mechanisms involved. The team says the model may also help test substances or biological factors that alter the pace of this process.
The focus on neural stem cells gives the research relevance to neuroscience. Age is a major risk factor for neurodegenerative conditions such as Alzheimer’s disease, as the study’s lead researcher noted. But the experiments do not show that these cells prevent, treat or reverse such diseases. They also do not establish that rejuvenating cells in a dish would improve health or extend life in humans.
The distinction matters: a younger reading on an epigenetic clock is a laboratory result about a cell sample. Whether that reading corresponds to durable function, safety or clinical benefit requires separate evidence. The researchers report that the cells behave like young cells, but this finding does not by itself establish a treatment or an outcome in patients.
As an affiliate, we earn on qualifying purchases.
Direct Conversion Versus Two-Step Reprogramming
Cells in the body share the same genetic makeup but usually take on specialised roles as they develop. A blood cell does not naturally become a neuron. In laboratory reprogramming, researchers use transcription factors to alter a cell’s developmental instructions and direct it toward another identity.
The Bonn group says earlier methods had shown age-related rejuvenation during a two-step process: a mature cell is first turned into a pluripotent stem cell and then guided into a more specialised cell type, such as a neural stem cell. In the current study, the researchers bypassed that pluripotent stage, converting blood-cell precursors directly into neural stem cells. They report that this approach produced a slower, trackable reset of epigenetic clocks.
The team had previously reported that nerve cells produced through related reprogramming work formed connections with existing neurons after transplantation into mouse brains. That earlier result is background to the research programme; it does not establish that the cells in this study are safe or effective as a human treatment. The current report centres on cell conversion and molecular-age measurements.
““We have directly converted red blood cell precursors into neural stem cells.””
— Prof. Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at University Hospital of Bonn
As an affiliate, we earn on qualifying purchases.
From Clock Readings to Human Benefit
The report describes changes in epigenetic age measurements, but the supplied study summary does not establish how long those changes persist, whether they occur consistently across donors, or how well they predict long-term cell function. It is also unclear from the report how the method performs across different cell samples and what risks might arise from the reprogramming process.
No treatment in people was tested. The findings do not show that a person’s body has been rejuvenated, that the cells can safely be used in patients, or that they can prevent or treat neurodegenerative disease. Further work would be needed to assess the cells’ stability, safety and function, and to determine whether the laboratory findings have clinical relevance.
As an affiliate, we earn on qualifying purchases.
Further Tests on Reprogramming
The researchers say the next research opportunity is to use the slow conversion process to examine which factors influence the pace at which epigenetic clocks reset. In principle, the model could support experiments testing candidate factors or substances, although the supplied report does not identify a specific clinical candidate or set out a timeline for such work.
Readers should look for further published results that test the process in additional samples and examine cell function and safety beyond age-clock readings. Any move toward treatment would require substantial further research; the study provides no confirmed schedule for clinical testing.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the Bonn researchers do?
They report converting human red blood cell precursors directly into neural stem cells in laboratory experiments, then tracking changes in epigenetic age markers.
Does this mean an 80-year-old person’s body became younger?
No. The reported age of less than 20 years refers to an epigenetic clock reading in cells after reprogramming in a test tube. The study did not report a change in the donor’s body or health.
What is an epigenetic clock?
It is a way of estimating cellular age from DNA modifications associated with aging. These modifications relate to how genetic information is regulated and do not change the underlying DNA sequence.
Could this approach treat Alzheimer’s disease?
The study did not test an Alzheimer’s treatment. Its findings may support research into cell aging, but they do not show that the method prevents or treats neurodegenerative disease.
Why does the gradual process matter?
The researchers tracked changes for more than 100 days. They say that slower timeline could help scientists study what affects the pace of cellular reprogramming and age-marker changes.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
